Biosimilar Monoclonal Antibodies
The global Biosimilar Monoclonal Antibodies market was valued at 4608.78 Million USD in 2021 and will grow with a CAGR of 29.52% from 2021 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.
By Market Verdors
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy`s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals
By Types
Infliximab
Rituximab
Trastuzumab
Adalimumab
By Applications
Oncology
Autoimmune Disease
Key Indicators Analysed
Market Players & Competitor AnalysisThe report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market AnalysisThe report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market TrendsMarket key trends which include Increased Competition and Continuous Innovations.
Opportunities and DriversIdentifying the Growing Demands and New Technology
Porters Five Force AnalysisThe report provides with the state of competition in industry depending on five basic forcesthreat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements
Table of Content
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Biosimilar Monoclonal Antibodies Revenue
1.4 Market Analysis by Type
1.4.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Infliximab
1.4.3 Rituximab
1.4.4 Trastuzumab
1.4.5 Adalimumab
1.5 Market by Application
1.5.1 Global Biosimilar Monoclonal Antibodies Market Share by Application: 2022-2027
1.5.2 Oncology
1.5.3 Autoimmune Disease
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Biosimilar Monoclonal Antibodies Market
1.8.1 Global Biosimilar Monoclonal Antibodies Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Biosimilar Monoclonal Antibodies Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biosimilar Monoclonal Antibodies Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Biosimilar Monoclonal Antibodies Sales Volume Market Share by Region (2016-2021)
3.2 Global Biosimilar Monoclonal Antibodies Sales Revenue Market Share by Region (2016-2021)
3.3 North America Biosimilar Monoclonal Antibodies Sales Volume
3.3.1 North America Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.3.2 North America Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Biosimilar Monoclonal Antibodies Sales Volume
3.4.1 East Asia Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.5.1 Europe Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.6.1 South Asia Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.7.1 Southeast Asia Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.8.1 Middle East Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.9.1 Africa Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.10.1 Oceania Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.11.1 South America Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.11.2 South America Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Biosimilar Monoclonal Antibodies Sales Volume (2016-2021)
3.12.1 Rest of the World Biosimilar Monoclonal Antibodies Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Biosimilar Monoclonal Antibodies Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Biosimilar Monoclonal Antibodies Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Biosimilar Monoclonal Antibodies Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Biosimilar Monoclonal Antibodies Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Biosimilar Monoclonal Antibodies Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Biosimilar Monoclonal Antibodies Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Biosimilar Monoclonal Antibodies Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Biosimilar Monoclonal Antibodies Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Biosimilar Monoclonal Antibodies Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Biosimilar Monoclonal Antibodies Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Biosimilar Monoclonal Antibodies Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Biosimilar Monoclonal Antibodies Sales Volume Market Share by Type (2016-2021)
14.2 Global Biosimilar Monoclonal Antibodies Sales Revenue Market Share by Type (2016-2021)
14.3 Global Biosimilar Monoclonal Antibodies Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Biosimilar Monoclonal Antibodies Consumption Volume by Application (2016-2021)
15.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Biosimilar Monoclonal Antibodies Business
16.1 Celltrion
16.1.1 Celltrion Company Profile
16.1.2 Celltrion Biosimilar Monoclonal Antibodies Product Specification
16.1.3 Celltrion Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Pfizer (Hospira)
16.2.1 Pfizer (Hospira) Company Profile
16.2.2 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Specification
16.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 3SBIO
16.3.1 3SBIO Company Profile
16.3.2 3SBIO Biosimilar Monoclonal Antibodies Product Specification
16.3.3 3SBIO Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Novartis (Sandoz)
16.4.1 Novartis (Sandoz) Company Profile
16.4.2 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Specification
16.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Dr Reddy`s
16.5.1 Dr Reddy`s Company Profile
16.5.2 Dr Reddy`s Biosimilar Monoclonal Antibodies Product Specification
16.5.3 Dr Reddy`s Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Celgen Biopharma
16.6.1 Celgen Biopharma Company Profile
16.6.2 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Specification
16.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Cadila Healthcare
16.7.1 Cadila Healthcare Company Profile
16.7.2 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Specification
16.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Hisun Pharma
16.8.1 Hisun Pharma Company Profile
16.8.2 Hisun Pharma Biosimilar Monoclonal Antibodies Product Specification
16.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Torrent Pharmaceuticals
16.9.1 Torrent Pharmaceuticals Company Profile
16.9.2 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Specification
16.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Biosimilar Monoclonal Antibodies Manufacturing Cost Analysis
17.1 Biosimilar Monoclonal Antibodies Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
17.4 Biosimilar Monoclonal Antibodies Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Biosimilar Monoclonal Antibodies Distributors List
18.3 Biosimilar Monoclonal Antibodies Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Biosimilar Monoclonal Antibodies (2022-2027)
20.2 Global Forecasted Revenue of Biosimilar Monoclonal Antibodies (2022-2027)
20.3 Global Forecasted Price of Biosimilar Monoclonal Antibodies (2016-2027)
20.4 Global Forecasted Production of Biosimilar Monoclonal Antibodies by Region (2022-2027)
20.4.1 North America Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.3 Europe Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.7 Africa Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.9 South America Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Biosimilar Monoclonal Antibodies Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Biosimilar Monoclonal Antibodies by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.2 East Asia Market Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.3 Europe Market Forecasted Consumption of Biosimilar Monoclonal Antibodies by Countriy
21.4 South Asia Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.5 Southeast Asia Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.6 Middle East Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.7 Africa Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.8 Oceania Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.9 South America Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
21.10 Rest of the world Forecasted Consumption of Biosimilar Monoclonal Antibodies by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices